bioTheranostics develops innovative molecular diagnostic oncology tests that provide valuable diagnostic and prognostic information to assist physicians in identifying the cancer therapies that will be most effective for each individual patient.

THEROS CancerTYPE ID^® provides molecular classification of uncertain or unknown cancers to guide physicians in determination of the primary cancer site and aides in the selection of therapeutic options.

THEROS Breast Cancer Index^SM predicts breast cancer recurrence risk based on proprietary molecular biomarkers, resulting in more appropriate treatment decisions.